Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma Clinical Trial

Official title:

Efficacy and Safety of Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06370065
• Other study ID #: HLX10IIT70-TJ
• Status: Recruiting
• Phase: Phase 2
• Start date: April 27, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Huikai Li, MD
• Phone: 18622228639
• Email: tjchlhk[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Willing to attend the study and having given the ICF

2. Age =18

3. Have a HCC diagnosis confirmed by radiology, histology, or cytology HCC is diagnosed at Barcelona Clinic Liver Cancer (BCLC) Stage C

4. Have not accepted any of systemic therapy for HCC such as systemic chemotherapy, molecular targeted drugs, immunotherapy.

5. At least 1 measurable intrahepatic lesion suitable for repeat assessments according to RECISTv1.1 criteria and it has not undergone surgery, radiology and/or other regional therapy (including but not limited to radiofrequency ablation, percutaneous ethanol injection, freezing therapy, high intensity focused ultrasound, transcatheter arterial chemoembolization, transcatheter arterial embolization). But if it progressed after the regional therapy, it could be selected as a target lesion. The local regional therapy must be done 4 weeks before randomization and the related AEs must recover to = CTCAE grade 1.

6. Child-Pugh score =7

7. Eastern Cooperative Oncology Group (ECOG) 0 or 1

8. Expected life time is over 12 weeks.

9. HBV-DNA < 2000 IU/mL

10. Organs function:

Platelet count =75×109/L Absolute neutrophil count (ANC) =1.5×109 /L White blood cell count =3.0×109 /L Haemoglobin =9.0 g/dL Serum total bilirubin =1.5×ULN ALT =5×ULN, and AST =5×ULN(ALT =3×ULN, and AST =3×ULN, if HCV-RNA is detectable) Albumin =28 g/L INR =1.5×ULN PT =1.5×ULN APTT =1.5×ULN Creatinine clearance (CL) >50 mL/min or serum creatinine =1.5×ULN Urine protein =1+ or =1.0g/24h 12. Patient is not fertile or willing and able to obey effective contraception

Exclusion Criteria:

1. Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC

2. History of hepatic encephalopathy

3. History of GI bleeding within 6 months, or investigator defined with high risk of haemorrhage for esophageal varices

4. With distant metastasis (hilar lymph nodes metastasis is allowed)

5. Co-infection of HBV and HCV

6. History of other malignancy within 5 years except for healed local tumor.

7. History of or plan to accept allogenic organ transplantation

8. Ascites requiring invasive intervention (e.g. paracentesis) to maintain symptomatic control (every month or more often)

9. History of myocardial infarction or unstable angina or uncontrolled arrythmia or stroke or cerebral hemorrhage within 6 months prior to randomization. QTcF value =450ms(male)or =470ms(female) detected by 12-lead electrocardiogram.

10. New York Heart Association Grade =2 congestive heart failure or LVEF <50%

11. Uncontrolled hypertension

12. History of hypertensive crisis or hypertensive encephalopathy

13. Active infection including but not limited to tuberculosis and HIV

14. With interstitial lung disease, lung fibrosis, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia and serious impairment in lung function

15. Active autoimmune disorders except patients with substitutional treatment with thyroid hormone and type I diabetes under treatment with insulin.

16. Receipt of live attenuated vaccine within 28 days prior to randomization

17. Current or prior use of steroids (>10mg/d prednisone) or immunosuppressive medication within 14 days before randomization

18. Significant traumatic injury or major surgical procedure within 28 days prior to randomization

19. Receipt of checkpoint inhibitors or T cell costimulatory drugs

20. Receipt of bevacizumab or its analogues

21. Involved in another clinical trial less than 14 days before randomization

22. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients

23. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control

24. Active bleeding, with history of =grade 3 bleeding within 6 months, or =grade 2 bleeding within 3 months

25. Use of anti-thrombotics within 5 days prior to randomization

26. In need of NSAIDs for long-term treatment. 26.With one of the following diseases within 6 months before randomization:(1) Digestive fistula, perforation and abscess (2) Gastrointestinal obstruction (3) Abdominal infection or inflammation (4) Major vascular disease 28. With severe and green wound, active ulcer or untreated fracture 29. History of drug abuse 30. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to screen for the study

Related Conditions & MeSH terms

• Advanced Hepatocellular Carcinoma
• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• HAIC+Serplulimab(HLX10)+ Bevacizumab Biosimilar(HLX04)
PD-1 inhibitor

Locations

Country	Name	City	State
China	Tianjin Cancer Hospital Airport Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Defined as proportion of patients who have a best response of CR or PR	up to 1year
Secondary	PFS	Defined as the time from enrollment to disease progression or death (whichever occurs first)	up to 1 year
Secondary	OS	Defined as the time from enrollment to death from any cause	up to 2 years